UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000001437
Receipt number R000001745
Scientific Title Phase II study of FOLFIRI plus Bevacitumab in the treatment of Japanese patients with advanced colorectal cancer.
Date of disclosure of the study information 2008/10/20
Last modified on 2013/08/23 09:11:14

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Phase II study of FOLFIRI plus Bevacitumab in the treatment of Japanese patients with advanced colorectal cancer.

Acronym

JACCRO CC-03

Scientific Title

Phase II study of FOLFIRI plus Bevacitumab in the treatment of Japanese patients with advanced colorectal cancer.

Scientific Title:Acronym

JACCRO CC-03

Region

Japan


Condition

Condition

Colorectal cancer

Classification by specialty

Gastroenterology Gastrointestinal surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the efficacy and the safety of FOLFIRI/Bevacitumab as a first line chemotherapy for the Japanese patients with advanced colorectal cancer.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Phase II


Assessment

Primary outcomes

Progression free survival

Key secondary outcomes

Time to tretment failure
Overall survival
Response rete
Safety


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

(1) Bevaciumab 5mg/Kg i.v. 90min.
(2) CPT-11 150mg/m2 i.v. 90min. and Isovorin 200mg/m2 i.v. 90min.
(3) 5-FU 400mg/m2 i.v. bolus and
5-FU 2400mg/m2 civ. 46 hours

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

74 years-old >=

Gender

Male and Female

Key inclusion criteria

(1) Histologically proven colorectal carcinoma.
(2)Writtened informed consent.
(3) Age 20-74.
(4) PS 0-1 (ECOG)
(5) Expected 3 months or over survival.
(6) Inoperable or reccurent colorectal cancer.
(7) No prior chemotherapy.
(8) Needs evaluable lesion.
(9) Needs adequate hematological function.

Key exclusion criteria

(1) Contraindications of using CPT-11, Bevacitumab, 5-FU and Leucovorin
(2) Having double or more cancers within 5 yeras.
(3).Pregnancy or lactation women, or women with suspected pregnancy or men with willing to get pregnant.
(4) Any subject judged by the investigator to be unfit for any reason to participate in the study

Target sample size

40


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Mitsugu Kochi

Organization

Nihon Universuty School of Medicine

Division name

Department of Digestive Surgery

Zip code


Address

30-1, Oyaguchi-kamimachi, Itabashi-ku, Tokyo

TEL

03-3972-8111

Email

kochi.mitsugu@nihon-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Toshifusa Nakajima

Organization

Japan Clinical Cancer Research Organization

Division name

Chief Director

Zip code


Address

3-10-6, Ariake, Kotoku, Tokyo

TEL

03-3570-0437

Homepage URL


Email

jaccro@jaccro.or.jp


Sponsor or person

Institute

Japan Clinical Cancer Research Organization

Institute

Department

Personal name



Funding Source

Organization

Japan Clinical Cancer Research Organization

Organization

Division

Category of Funding Organization

Non profit foundation

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2008 Year 10 Month 20 Day


Related information

URL releasing protocol


Publication of results

Published


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2008 Year 09 Month 18 Day

Date of IRB


Anticipated trial start date

2008 Year 10 Month 01 Day

Last follow-up date

2011 Year 06 Month 01 Day

Date of closure to data entry

2011 Year 12 Month 01 Day

Date trial data considered complete

2012 Year 06 Month 01 Day

Date analysis concluded

2012 Year 06 Month 01 Day


Other

Other related information



Management information

Registered date

2008 Year 10 Month 18 Day

Last modified on

2013 Year 08 Month 23 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001745


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name